enGene next stop for Ron Cooper

24 July 2024

Genetic medicines company enGene Holdings (Nasdaq: ENGN) has named Ron Cooper (pictured, above) its new chief executive.

This transition follows a previously announced succession plan for Jason Hanson, who will remain a strategic advisor to the company, which is conducting a pivotal study with its non-viral, intravesical lead product candidate, EG-70, in BCG-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC).

Mr Cooper most recently served as president and chief executive of Albireo Pharma, a fully integrated global commercial biopharmaceutical company that Ipsen (Euronext: IPN) acquired in 2023.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK